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Diabetic Retinopathy is the leading cause
of new blindness in the 25 to 74 year age
group in the United States. The diabetic
patient has a twenty-five times greater risk of
developing blindness than the non-diabetic
patient. Only 50% of all patients with diabe
tes mellitus have actually been diagnosed.1
The Community Epidemiologic Work Group
for Diabetes Mellitus in Hawaii showed a
prevalence of 25.2 per 1000 to 63 per 1000
persons based on self-reported data. The
State Blind Registry for 1992-1993 showed
diabetic retinopathy as the second leading
cause of all new blind cases (20.9%).2 Dia
betic retinopathy is a significant cause for
concern in Hawaii in regard to patient quality
of life and socioeconomic concerns.
Various factors have been studied in the
pathophysiology of Diabetic Retinopathy to
include aldose reductase, growth hormone,
blood rheology abnormalities, blood viscos
ity,’ vascular endothelial growth factor,3etc.
It is as yet not fully understood how much
each of these (or other unknown factors)
contributes to the retinal vascular disease
process.
Duration of diabetes mellitus is critical
relative to the onset of retinopathy. Type I
diabetics usually have no retinopathy until
five years after diagnosis. By 15 years into
the disease 90% will have retinopathy. Type
II diabetics can present with retinopathy on
initial diagnosis. The recommendation for
dilated eye examination in the Type I dia
betic is yearly once the patient has had diabe
tes for five years. Type II diabetics should be
examined yearly from time of diagnosis.’
Definite risk factors for diabetic retinopa
thy include duration of disease, poor glucose
control, hypertension, and renal disease.4As 87% of patients with
advanced retinopathy have nephropathy andlor neuropathy, patients
with nephropathy and/or neuropathy definitely need an ophthalmo
logic exam.’
Diabetic Retinopathy has two major classifications—Non-Prolif
erative Diabetic Retinopathy (NPDR) and Proliferative Diabetic
Retinopathy (PDR).’ In NPDR one sees retinal microaneurysms.
blot hemorrhages, cotton wool spots, intraretinal microvascular
abnormalities, and retinal edema (Fig 1). Edema affecting the
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macula causes loss of central (reading) vision. PDR is the more
advanced stage occurring when the retina starts to lose its blood
supply. The eye responds by growing new blood vessels on the optic
nerve or retina (Fig 2). These fragile new vessels bleed, filling the
vitreous cavity. Scar tissue accompanies the neovascularization and
can cause retinal detachment (Fig 3).
To combat Diabetic Retinopathy, surgical strategies were devel
oped in which Laser surgery treats macular edema and causes
atrophy of the neovascularization. Vitrectomy surgery removes
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dense vitreous hemorrhage and relieves traction retinal detachment
from scarring.
The Early Treatment Diabetic Retinopathy Study (ETDRS)6
demonstrated a 50% reduction in loss of vision with appropriate
laser surgery for clinically significant macular edema (Fig 4). This
study also showed that aspirin did not reduce progression ofdiabetic
retinopathy nor increase the risk of vision loss from vitreous
hemorrhage.7The Diabetic Retinopathy Study showed a 50-60%
reduction in vision loss for timely laser surgery in patients with
Proliferative Diabetic Retinopathy (Fig 5).8 The Diabetic Retinopa
thy Vitrectomy Study showed better visual result with early
vitrectomy surgery in Type I Diabetics with nonclearing vitreous
hemorrhage (Fig 6).
The Diabetes Control and Complications Trial (DCCT) showed
delay in onset and slower progression of Diabetic Retinopathy,
nephropathy, and neuropathy. There was a 50% reduction in amount
of laser surgery for Diabetic Retinopathy in tightly controlled
diabetics.1°
Diabetic Retinopathy is the major cause of new blindness in
working Americans. The longer the duration ofdiabetes, the greater
the risk of retinopathy. Excellent serum glucose, blood pressure,
and cholesterol control11delay and decrease the severity ofretinopa
thy. Timely laser surgery reduces vision loss by 50%. It is the
responsibility of all physicians in partnership to diagnose and
properly manage the diabetic patient.
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Correction
Please note that the above manuscript on Diabetic Retinopathy by John H. Drouilhet MD, was originally published (Haw Med. J.
1997;56:241-244) with incorrect illustrations. We reprint the corrected manuscript and illustrations in its entirety. We apologize to the
author and to the reader for the error.
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